Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of lamivudine and adefovir dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg)
adefovir/lamivudine
LAF114957
NCT01353742
Hepatitis B, Chronic
Phase 1
 
February 2017

Powered by ideaPoint, Inc.